PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to assess the activity of the combined use of Valproic
Acid (VPA)in combination with 5-Azacytidine (5-Aza C) in the treatment of MDS.
Activity will be evaluated as percentage of patients achieving complete or partial remission.